Wide Ranks

EPRX

Eupraxia Pharmaceuticals Inc.

3.45

Top Statistics
Market Cap 122 M Forward PE 0.0000 Revenue Growth 0.00 %
Current Ratio 2.11 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -2.91 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 23 M Total Cash Per Share 0.6550 Total Debt 4 M
Total Debt To Equity 34.94 Current Ratio 2.11 Book Value Per Share 0.0810
All Measures
Short Ratio 2774.00 % Message Board Id finmb_225412256 Shares Short Prior Month 128439
Return On Equity -3.14 City Victoria Uuid 7f042560-af28-3f26-97cb-193031135fb0
Previous Close 3.14 First Trade Date Epoch Utc 1 B Book Value 0.0810
Beta 1.23 Total Debt 4 M Volume 5636
Price To Book 42.59 Fifty Two Week Low 2.20 Total Cash Per Share 0.6550
Shares Short Previous Month Date 1 B Max Age 86400 Sand P52 Week Change 0.3133
Net Income To Common -26998596 Ask 3.80 Implied Shares Outstanding 38 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 37510
Average Volume10days 37510 Total Cash 23 M Next Fiscal Year End 1 B
Held Percent Insiders 0.1112 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 3.14 Target Low Price 0.0000
Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.79 Open 3.06
Free Cashflow -14615146 State BC Dividend Yield 0.00 %
Return On Assets -0.9868 Time Zone Short Name EST Trailing Eps -0.9300
Day Low 3.06 Address1 2067 Cadboro Bay Road Shares Outstanding 35 M
Price Hint 4 Target High Price 0.0000 Website https://www.eupraxiapharma.com
52 Week Change 0.1695 Average Volume 15040 Recommendation Key none
Forward Eps 0.0000 Compensation As Of Epoch Date 1 B Quick Ratio 202.30 %
Is_sp_500 False Regular Market Day High 3.56 Profit Margins 0.00 %
Debt To Equity 34.94 Fifty Two Week High 4.08 Day High 3.56
Shares Short 128163 Regular Market Open 3.06 Industry Key biotechnology
Bid 3.11 Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0036 Operating Cashflow -25676896 Currency USD
Time Zone Full Name America/New_York Market Cap 122 M Is_nasdaq_100 False
Zip V8R 5G4 Quote Type EQUITY Industry Biotechnology
Long Name Eupraxia Pharmaceuticals Inc. Regular Market Day Low 3.06 Held Percent Institutions 0.1285
Current Price 3.45 Address2 Suite 201 Enterprise To Ebitda -2.91
Financial Currency USD Current Ratio 2.11 Industry Disp Biotechnology
Country Canada Float Shares 28 M Two Hundred Day Average 2.73
Enterprise Value 92 M Forward PE 0.0000 Regular Market Volume 5636
Ebitda -31763176 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector.

The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery.

It also is involved in the development of product candidates for oncology.

The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.

Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.